Amended Report of Foreign Issuer (6-k/a)
01 Mai 2014 - 9:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
Amendment No. 1
Report of
Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of May 2014
Commission File Number 001-16174
TEVA
PHARMACEUTICAL INDUSTRIES LIMITED
(Translation of registrants name into English)
5 Basel Street, P.O. Box 3190
Petach Tikva 4951033 Israel
(Address of principal executive offices)
Indicate by
check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F
x
Form 40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7):
¨
CONTENTS
This Report on Form 6-K consists of the following documents, which are attached hereto and incorporated by reference herein:
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
|
|
|
|
|
Date: May 1, 2014
|
|
|
|
By:
|
|
/S/ EYAL DESHEH
|
|
|
|
|
Name:
|
|
Eyal Desheh
|
|
|
|
|
Title:
|
|
EVP & CFO
|
2
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024